Oxana Komina - Concepedia

Author

Oxana Komina

Medical University of Vienna

Also Known As

Central Siberian botanical garden, Siberian branch, RAS, Komina, O., O. Komina, OXANA KOMINA, Oxana Komina

Publications

364

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Comprehensive Cancer Center Vienna University of Milan

About

Oxana Komina is an author at Medical University of Vienna specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	222
2	Cell Biology	6	6	181
3	Health Sciences	2	2	73
4	Natural Sciences	1	1	26
5	Biochemistry	1	1	26

Oxana Komina

Publications

341

Citations

H-Index

Page 1

	Year	Citations
Whether to target single or multiple CDKs for therapy? That is the question Józefa Węsierska‐Gądek, Margarita Maurer‐Granofszky, Nora Zulehner, Journal of Cellular Physiology Chemoprevention StrategyPharmacotherapyCell CycleImmunotherapyTumor Biology	2010	49
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen‐induced phosphorylation of ER‐α in human ER‐positive breast cancer cells Józefa Węsierska‐Gądek, David Gritsch, Nora Zulehner, Journal of Cellular Biochemistry Breast OncologyCell DeathCell CycleCancer BiologyMammary Gland Development	2010	46
Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway Zsuzsanna Bagó-Horváth, Wolfgang Sieghart, Michael Grusch, Neuroendocrinology	2012	31
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells Józefa Węsierska‐Gądek, Nora Zulehner, Franziska Ferk, Biochemical Pharmacology Different Brca1Breast OncologyParp InhibitionTopoisomerase IiMedicine	2012	30
Characterization of Autoantibodies against Components of the Nuclear Pore Complexes Józefa Węsierska‐Gądek, ANNA KLIMA, Oxana Komina, Annals of the New York Academy of Sciences Immunocytochemical TechniqueImmunologyGlycobiologyMolecular BiologyNuclear Pore Complexes	2007	26
Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment Józefa Węsierska‐Gądek, Andreea Borza, Eva Walzi, Journal of Cellular Biochemistry	2009	26
Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential. Józefa Węsierska‐Gądek, Andreea Borza, Oxana Komina, Acta Biochimica Polonica Therapeutic PotentialCell ProliferationCell CycleTumor BiologyOncology	2009	24
Roscovitine Differentially Affects Asynchronously Growing and Synchronized Human MCF‐7 Breast Cancer Cells Margarita Maurer‐Granofszky, Oxana Komina, Józefa Węsierska‐Gądek Annals of the New York Academy of Sciences	2009	23
Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells Oxana Komina, Józefa Węsierska‐Gądek Biochemical Pharmacology Hematological MalignancyCell Cycle ProgressionCdk InhibitorMedicineMalignant Blood Disorder	2008	21
R‐roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase‐dependent apoptosis Małgorzata Rogalińska, Jerzy Z. Błoński, Oxana Komina, Journal of Cellular Biochemistry	2009	20

Page 1